Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

November 13, 2024

Study Completion Date

September 30, 2025

Conditions

Light Chain (AL) AmyloidosisCCND1 TranslocationVenetoclax

Interventions

DRUG

Venetoclax

Venetoclax 400mg po qd for 1 year

DRUG

Dexamethasone Oral

Dexamethasone 40mg po qw for the first 6 months, then 10mg po qw for the next 6 months

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Peking Union Medical College Hospital

OTHER

NCT05996406 - Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) | Biotech Hunter | Biotech Hunter